BioGaia Stock
BioGaia Stock price
Key metrics
Is BioGaia a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.
BioGaia Stock Analysis
Analyst Opinions
6 Analysts have issued a BioGaia forecast:
Analyst Opinions
6 Analysts have issued a BioGaia forecast:
Financial data from BioGaia
| Mar '25 |
+/-
%
|
||
| Revenue | 126 126 |
9%
9%
|
|
| Gross Profit | 92 92 |
8%
8%
|
|
| EBITDA | 36 36 |
13%
13%
|
EBIT (Operating Income) EBIT | 34 34 |
14%
14%
|
| Net Profit | 28 28 |
17%
17%
|
|
In millions EUR.
Don't miss a Thing! We will send you all news about BioGaia directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden.
| Head office | Sweden |
| CEO | Theresa Agnew |
| Employees | 225 |
| Founded | 1990 |
| Website | sv.biogaia.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
